Tsvetelina Pencheva Hoang
Hoofd Techniek/Wetenschap/O&O bij MARKER THERAPEUTICS, INC.
Vermogen: - $ op 30-04-2024
Profiel
Tsvetelina Pencheva Hoang is currently the Vice President-Research & Development at Marker Therapeutics, Inc. She previously worked as the Director-Translational Research at Bellicum Pharmaceuticals, Inc. from 2015 to 2018.
Before that, she was a Member at Memorial Sloan Kettering Cancer Center.
From 2013 to 2015, she worked as a Member at The University of Texas M.D.
Anderson Cancer Center.
She also held a position as a Member at The Phi Beta Kappa Society.
Dr. Hoang holds a doctorate degree from The Johns Hopkins University and undergraduate and graduate degrees from Yale University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 27-02-2023 | 0 ( -.--% ) | - $ | 30-04-2024 |
Actieve functies van Tsvetelina Pencheva Hoang
| Bedrijven | Functie | Begin |
|---|---|---|
| MARKER THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 23-10-2018 |
Eerdere bekende functies van Tsvetelina Pencheva Hoang
| Bedrijven | Functie | Einde |
|---|---|---|
| BELLICUM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-07-2018 |
The Phi Beta Kappa Society
 The Phi Beta Kappa Society Miscellaneous Commercial ServicesCommercial Services The Phi Beta Kappa Society operates as an organization for liberal arts and science education. The non-profit company is based in Washington. | Corporate Officer/Principal | - |
Opleiding van Tsvetelina Pencheva Hoang
| Yale University | Graduate Degree |
| The Johns Hopkins University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| MARKER THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Bellicum Pharmaceuticals, Inc.
 Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX. | Health Technology |
The Phi Beta Kappa Society
The Phi Beta Kappa Society Miscellaneous Commercial ServicesCommercial Services The Phi Beta Kappa Society operates as an organization for liberal arts and science education. The non-profit company is based in Washington. | Commercial Services |
